Chemoprevention of carcinoma prostate: A review

被引：11

作者：

Ansari M.S. ^{[1
]}

Gupta N.P. ^{[1
]}

Hemal A.K. ^{[1
]}

机构：

[1] Department of Urology, All India Institute of Medical Sciences, New Delhi

来源：

International Urology and Nephrology | 2002年 / 34卷 / 2期

关键词：

Prostate Cancer; Selenium; Carotenoid; Lycopene; Prospective Clinical Trial;

D O I：

10.1023/A:1023297725004

中图分类号：

学科分类号：

摘要：

Purpose: Chemoprevention of prostate cancer is the administration of agents to prevent, inhibit, or delay progression of prostate cancer. Opportunities exist for testing various types of chemopreventive interventsion. Material and methods: The authors reviewed the relevant articles published in the last twenty years and studied the biology of the prostate cancer. An attempt is made to identify intermediate markers and surrogate endpoint markers. The various interventions and initial clinical trial results are described. End points for evaluation are mainly based on changes in PSA, changes of histological precursors, or time of onset of clinical disease. Results: Nutritional factors such as reduced fat intake, vitamin A, vitamin E, vitamin C, vitamin D, Lycopene and selenium may have a protective effect against prostate cancer. Conclusion: Numerous studies implicate dietary and nutritional factors in the onset and progression of prostate cancer. Hence, it is possible that bioactive compounds (anti-oxidants) like vits. A, C, D, E, minerals like selenium and carotenoids like lycopene can be a part of chemopreventive strategies for prostate cancer. Ongoing studies on nutrition and prostate cancer may bring the required evidence to support what is still only a hypothesis at present. However, absolute recommendation will have to await the results of long term prospective clinical trials.

引用

页码：207 / 214

页数：7

共 42 条

[1]

Albanes D., Heinonen O.P., Huttunen J.K., Et al., Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the alpha-Tocopherol Bet-Carotene Cancer Prevention, Am J Clin Nutr, 62, (1995)

[2]

Alberts S.R., Blute M.L., Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia, Urology, 57, 4, pp. 188-190, (2001)

[3]

Kamat A.M., Lamm D.L., Chemoprevention of urological cancer, J Urol, 161, pp. 1748-1760, (1999)

[4]

Benedict W.F., Jones P.A., Inhibition of transformation and oncologic progression by ascorbic acid: A possible role in chemoprevention, Molecular Interrelations of Nutrition and Cancer, (1982)

[5]

Boone C.W., Kelloff G.J., Biomarker end-points in cancer chemoprevention trials, IARC Sci Publ, 142, pp. 273-280, (1997)

[6]

Boone C.W., Bacus J.W., Bacus J.V., Et al., Properties of intraepithelial neoplasia relevant to cancer chemoprevention and to the development of surrogate end points for clinical trials, Proc Soc Exp Biol Med, 216, 2, pp. 151-165, (1997)

[7]

Bosland M.C., Use of animal models in defining efficacy of chemoprevention agents against prostate cancer, Eur Urol, 35, 5-6, pp. 459-463, (1999)

[8]

Bostwick D.G., Prostatic intraepithelial neoplasia is a risk factor for cancer, Semin Urol Oncol, 17, 4, pp. 187-198, (1999)

[9]

Bostwick D.G., Montironi R., Sesterhenn I.A., Diagnosis of prostatic intraepithelial neoplasia: Prostate Working Group/consensus report, Scand J Urol Nephrol Suppl, 205, pp. 3-10, (2000)

[10]

Brooks J.D., Weinstein M., Lin X., Et al., CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia, Cancer Epidemiol Biomarkers Prev, (1998)

← 1 2 3 4 5 →